(Q44044223)

29 November 2017

title

Nutritional advantages of probiotics and prebiotics (English)

1 reference

29 November 2017

0 references

Marteau P

1

1 reference

29 November 2017

Boutron-Ruault MC

series ordinal

2

1 reference

29 November 2017

publication date

1 May 2002

1 reference

British Journal of Nutrition

29 November 2017

published in

1 reference

29 November 2017

volume

87 Suppl 2

1 reference

29 November 2017

page(s)

S153-7

1 reference

Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1079%2FBJN2002531

Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FBJN2002531

Calcium, phosphorus, vitamin D, dairy products and colorectal carcinogenesis: a French case--control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FBJN2002531

Nondigestible oligosaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FBJN2002531

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FBJN2002531

Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FBJN2002531

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FBJN2002531

Tolerance to low-digestible carbohydrates: symptomatology and methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FBJN2002531

Saccharomyces boulardii in maintenance treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FBJN2002531

Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FBJN2002531

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FBJN2002531

Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FBJN2002531

Altered colonic environment, a possible predisposition to colorectal cancer and colonic inflammatory bowel disease: rationale of dietary manipulation with emphasis on disaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FBJN2002531

A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FBJN2002531

The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FBJN2002531

21 January 2018

Identifiers

DOI

10.1079/BJN2002531

1 reference

29 November 2017

1 reference